| All patients†| Patients with TN tumors‡ | Patients with HR-pos tumors§ | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Variable | No. events/No. patients | Hazard ratio | 95% CI | P value | No. events/No. patients | Hazard ratio | 95% CI | P value | No. events/No. patients | Hazard ratio | 95% CI | P value |
pT-stage | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
pT1/pT2 | 65/200 | 1.00 | Â | Â | 17/44 | 1.00 | Â | Â | 48/156 | 1.00 | Â | Â |
pT3 | 22/37 | 1.93 | 1.16 - 3.21 | 0.012 | 10/13 | 2.46 | 1.03 - 5.88 | 0.043 | 12/24 | 1.71 | 0.88 - 3.32 | 0.114 |
Histologic grade | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
I/II | 48/147 | 1.00 | Â | Â | 7/15 | 1.00 | Â | Â | 41/132 | 1.00 | Â | Â |
III | 39/90 | 1.34 | 0.81 - 2.20 | 0.250 | 20/42 | 1.60 | 0.62 - 4.13 | 0.334 | 19/48 | 1.25 | 0.69 - 2.27 | 0.455 |
aCGH pattern* | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Non-BRCA-likeCGH tumor | 56/162 | 1.00 | Â | Â | 10/21 | 1.00 | Â | Â | 46/141 | 1.00 | Â | Â |
BRCA-likeCGH tumor | 31/75 | 1.78 | 0.97 - 3.24 | 0.061 | 17/36 | 2.11 | 0.72 - 6.19 | 0.173 | 14/39 | 1.79 | 0.82 - 3.92 | 0.143 |
BRCA-like CGH tumor* | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
FE90C chemotherapy | 25/40 | 1.00 | Â | Â | 14/20 | 1.00 | 1.00 | Â | 11/20 | 1.00 | Â | Â |
HD-CTC chemotherapy | 6/35 | 0.19†| 0.08 - 0.48 | <0.001 | 3/16 | 0.19‡ | 0.19‡ | 0.05 – 0.66 | 3/19 | 0.19§ | 0.05 - 0.71 | 0.013 |
Non-BRCA-like CGH tumor* |  |  | †Homogeneity: P = 0.004 |  |  | ‡Homogeneity: P = 0.034 |  |  | §Homogeneity: P = 0.048 | |||
FE90C chemotherapy | 30/79 | 1.00 | 5/10 | 1.00 | 25/69 | 1.00 | ||||||
HD-CTC chemotherapy | 26/83 | 0.89†| 0.52 - 1.50 | 5/11 | 5/11 | 1.31‡ | 0.37 - 4.64 | 0.676 | 21/72 | 0.82§ | 0.46 - 1.46 | 0.493 |